Glenmark Pharmaceuticals Limited Statistics
Want to see IN:GLENMARK full AI Analyst Report?
Glenmark Pharmaceuticals Limited (GLENMARK) Stock Statistics & Valuation Metrics
Total Valuation
Glenmark Pharmaceuticals Limited has a market cap or net worth of INR 745.92B. The enterprise value is INR 653.53B.
- Market Cap
- INR 745.92B
- Enterprise Value
- INR 653.53B
Share Statistics
Glenmark Pharmaceuticals Limited has 282,224,670 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 282,224,670
- Owned by Insiders
- ―
- Owned by Institutions
- 8.41%
Financial Efficiency
Glenmark Pharmaceuticals Limited’s return on equity (ROE) is 0.13 and return on invested capital (ROIC) is 20.12%.
- Return on Equity (ROE)
- 0.13
- Return on Assets (ROA)
- 0.07
- Return on Invested Capital (ROIC)
- 20.12%
- Return on Capital Employed (ROCE)
- 0.30
- Revenue Per Employee
- 10.02M
- Profits Per Employee
- 803.64K
- Employee Count
- 16,946
- Asset Turnover
- 0.85
- Inventory Turnover
- 2.59
Valuation Ratios
The current PE Ratio of Glenmark Pharmaceuticals Limited is 51.33. Glenmark Pharmaceuticals Limited’s PEG ratio is 1.17.
- PE Ratio
- 51.33
- PS Ratio
- 4.70
- PB Ratio
- 6.64
- Price to FCF
- 31.91
- Price to Operating Cash Flow
- 26.27
- PEG Ratio
- 1.17
Income Statement
In the last 12 months, Glenmark Pharmaceuticals Limited had revenue of 169.83B and earned 13.62B in profits. Earnings per share was 48.26.
- Revenue
- 169.83B
- Gross Profit
- 80.84B
- Operating Income
- 39.99B
- Pretax Income
- 19.85B
- Net Income
- 13.62B
- EBITDA
- 27.67B
- Earnings Per Share (EPS)
- 48.26
Cash Flow
In the last 12 months, operating cash flow was 28.36B and capital expenditures -5.00B, giving a free cash flow of 23.35B billion.
- Operating Cash Flow
- 28.36B
- Free Cash Flow
- 23.35B
- Free Cash Flow per Share
- 82.78
Dividends & Yields
Glenmark Pharmaceuticals Limited pays an annual dividend of INR 2.50, resulting in a dividend yield of 0.19%
- Dividend Per Share
- INR 2.50
- Dividend Yield
- 0.19%
- Payout Ratio
- 11.28%
- Free Cash Flow Yield
- 3.13%
- Earnings Yield
- 1.95%
Stock Price Statistics
- Beta
- 0.72
- 52-Week Price Change
- 40.85%
- 50-Day Moving Average
- 2376.75
- 200-Day Moving Average
- 2264.12
- Relative Strength Index (RSI)
- 70.71
- Average Volume (3m)
- 24.97K
Important Dates
Glenmark Pharmaceuticals Limited upcoming earnings date is Feb 05, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Feb 05, 2027
- Ex-Dividend Date
- Oct 03, 2025
Financial Position
Glenmark Pharmaceuticals Limited as a current ratio of 1.77, with Debt / Equity ratio of 5.65%
- Current Ratio
- 1.77
- Quick Ratio
- 1.23
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -0.21
- Interest Coverage Ratio
- 19.16
Taxes
In the past 12 months, Glenmark Pharmaceuticals Limited has paid 6.23B in taxes.
- Income Tax
- 6.23B
- Effective Tax Rate
- 0.31
Enterprise Valuation
Glenmark Pharmaceuticals Limited EV to EBITDA ratio is 27.03, with an EV/FCF ratio of 31.96.
- EV to Sales
- 4.71
- EV to EBITDA
- 27.03
- EV to Free Cash Flow
- 31.96
- EV to Operating Cash Flow
- 26.32
Balance Sheet
Glenmark Pharmaceuticals Limited has INR 11.76B in cash and marketable securities with INR 5.94B in debt, giving a net cash position of INR 5.83B billion.
- Cash & Marketable Securities
- INR 11.76B
- Total Debt
- INR 5.94B
- Net Cash
- INR 5.83B
- Net Cash Per Share
- INR 20.65
- Tangible Book Value Per Share
- INR 283.66
Margins
Gross margin is 48.52%, with operating margin of 16.69%, and net profit margin of 9.16%.
- Gross Margin
- 48.52%
- Operating Margin
- 16.69%
- Pretax Margin
- 12.01%
- Net Profit Margin
- 9.16%
- EBITDA Margin
- 17.42%
- EBIT Margin
- 13.28%
Analyst Forecast
The average price target for Glenmark Pharmaceuticals Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -0.11%
- EPS Growth Forecast
- 43.72%
Scores
- Smart Score
- ―
- AI Score
- 66

